Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate CancerBusiness Wire • 04/25/25
Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing To Fuel New Prostate and Bladder Cancer Insights Will Be Presented at AUA Annual MeetingBusiness Wire • 04/22/25
Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute's SEER Specialized Database ReleaseBusiness Wire • 04/21/25
The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It.Investors Business Daily • 04/17/25
Strength Seen in Veracyte (VCYT): Can Its 13.0% Jump Turn into More Strength?Zacks Investment Research • 04/10/25
Veracyte (VCYT) Up 0.7% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 03/26/25
Wall Street Analysts Believe Veracyte (VCYT) Could Rally 35.05%: Here's is How to TradeZacks Investment Research • 03/26/25
New Data Demonstrate Accuracy of Veracyte's Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder CancerBusiness Wire • 03/25/25
Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25Business Wire • 03/19/25
Diagnostic Company Veracyte Weighs Sale For French Subsidiary, Analyst Says 'Walking Away' Is A Long-Term PositiveBenzinga • 02/25/25
New Data at ASCO GU Show Power of Veracyte's Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer ResearchBusiness Wire • 02/14/25
Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests' Leadership in Urologic Cancers to Be Presented at the 2025 ASCO GU SymposiumBusiness Wire • 02/11/25
New Study Shows Veracyte's Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder CancerBusiness Wire • 02/05/25
Veracyte to Release Fourth Quarter and Full-Year 2024 Financial Results on February 24, 2025Business Wire • 02/04/25